임상 레이더 AI | ||
|---|---|---|
임상시험 NCT06997497은(는) 대장 선암, 직장 선암에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요. | ||
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
검색으로 돌아가기
머크A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) 3상 477 표적 치료
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT06997497은(는) 치료을(를) 알아보기 위한 연구입니다. 이 연구는 대장 선암, 직장 선암에 대해 진행되며, 3상 중재연구으로 현재 상태는 모집중입니다. 연구는 2025년 7월 16일에 시작되어 477명의 참여자를 모집하고 있습니다. 머크이(가) 진행하며, 2030년 10월 27일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 3월 30일에 갱신되었습니다.
간단한 개요
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.
Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding calderasib (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with th...
더 보기상세한 설명
This study will have 2 parts.
공식 제목
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)
질환명
대장 선암직장 선암기타 연구 식별자
- 1084-012
- MK-1084-012 (기타 식별자) (MSD)
- KANDLELIT-012 (기타 식별자) (MSD)
- 2024-517232-22-00 (등록 식별자) (EU CT)
- U1111-1311-8311 (등록 식별자) (UTN)
- jRCT2031250265 (등록 식별자) (Japan Registry of Clinical Trials (jRCT))
NCT 번호
실제 연구 시작일
2025-07-16
최신 업데이트 게시
2026-03-30
예상 연구 완료일
2030-10-27
계획된 등록 인원
477
연구종류
중재연구
단계/상
3상
상태
모집중
주요 목적
치료
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
단일맹검
시험군 / 개입
| 참가자 그룹/시험군 | 개입/치료 |
|---|---|
실험적Calderasib + Cetuximab + mFOLFOX6 Participants will receive calderasib orally, cetuximab per label every 2 weeks (Q2W), and mFOLFOX6 chemotherapy: oxaliplatin per label every 2 weeks (Q2W), leucovorin or levofolinate calcium per label Q2W, and 5-fluorouracil (5-FU) per label Q2W. Treatment will continue until criteria for discontinuation is met. | Calderasib Oral tablet Oxaliplatin Per label Leucovorin/levofolinate calcium Per label 5-Fluorouracil Per label Cetuximab Per label |
활성 대조군mFOLFOX6 Participants will receive mFOLFOX6 chemotherapy: oxaliplatin per label Q2W, leucovorin or levofolinate calcium per label Q2W, and 5-fluorouracil (5-FU) per label Q2W. Participants may also receive bevacizumab or bevacizumab biosimilar Q2W at the investigator's discretion. Treatment will continue until criteria for discontinuation is met. | Oxaliplatin Per label Leucovorin/levofolinate calcium Per label 5-Fluorouracil Per label Bevacizumab Per label Bevacizumab biosimilar Per label |
주요결과변수
이차결과변수
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Number of Participants Experiencing Dose-Limiting Toxicity (DLT) | A DLT is defined as the occurrence of protocol-specified toxicities if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration. | Up to approximately 28 days |
Part 1: Number of Participants Who Experience an Adverse Event (AE) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. | Up to approximately 44 months |
Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. | Up to approximately 44 months |
Progression Free Survival (PFS) | PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. | Up to approximately 44 months |
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Objective Response Rate (ORR) | ORR is defined as a confirmed complete response (CR: the disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). The percentage of participants who experience CR or PR as assessed by BICR will be presented. | Up to approximately 3 years |
Overall Survival (OS) | OS is defined as the time from randomization to death due to any cause. | Up to approximately 5 years |
Duration of Response (DOR) | For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented. | Up to approximately 4 years |
Part 2: Number of Participants with an Adverse Event (AE) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. | Up to approximately 5 years |
Part 2: Number of Participants who Discontinue Study Treatment Due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. | Up to approximately 5 years |
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life (QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score will be presented. A higher score indicates a better outcome. | Baseline and up to approximately 5 years |
Change from Baseline in the EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. Participant responses to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate better physical functioning. The change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) combined score will be presented. | Baseline and up to approximately 5 years |
Change from Baseline in the EORTC-QLQ-C30 Role Functioning (Items 6 and 7) Combined Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be presented. | Baseline and up to approximately 5 years |
Change from Baseline in the EORTC-QLQ-C30 Appetite Loss (Item 13) Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of life questionnaire, including a single-item scale score for appetite loss (QLQ-C30 Item 13). For this item, individual responses to the question "Have you lacked appetite?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 appetite loss (Item 13) scale score will be presented. | Baseline and up to approximately 5 years |
Change from Baseline in the EORTC-Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score | The EORTC QLQ-CR29 is a health-related quality-of life questionnaire specific for colorectal cancer, including a single-item scale score for bloating (QLQ-CR29 Item 37). For this item, individual responses to the question "Did you have a bloated feeling in your abdomen?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-CR29 bloating (Item 37) scale score will be presented. | Baseline and up to approximately 5 years |
Time to First Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in global health status (GHS) (EORTC QLQ-C30 Item 29) \& quality of life (QoL) combined score (EORTC QLQ-C30 Item 30). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QoL combined score, will be presented. A longer TTD indicates a better outcome. | Baseline and up to approximately 5 years |
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in physical functioning score (EORTC QLQ-C30 Items 1-5). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QoL combined score, will be presented. A longer TTD indicates a better outcome. | Baseline and up to approximately 5 years |
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate better role functioning. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in role functioning score, will be presented. A longer TTD indicates a better outcome. | Baseline and up to approximately 5 years |
TTD in EORTC QLQ-C30 Appetite Loss (Item 13) Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in appetite loss score (EORTC QLQ-C30 Item 13). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome. | Baseline and up to approximately 5 years |
TTD in EORTC QLQ-CR29 Bloating (Item 37) Score | The EORTC QLQ-CR29 is a health-related quality-of life questionnaire specific for colorectal cancer, including a single-item scale score for bloating (QLQ-CR29 Item 37). TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in bloating score (QLQ-CR29 Item 37). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in appetite loss score, will be presented. A longer TTD indicates a better outcome. | Baseline and up to approximately 5 years |
참여 도우미
적격성 기준
연령대
성인, 노인
최소 연령
18 Years
참여 가능한 성별
전체
The main inclusion criteria include but are not limited to the following:
- Has a histologically confirmed diagnosis of locally advanced unresectable or metastatic (unresectable Stage III or Stage IV as defined by American Joint Committee on Cancer \[AJCC\] eighth edition) colorectal adenocarcinoma
- Part 2 only: Has not received systemic anticancer therapy for locally advanced unresectable or metastatic colorectal cancer
- Tumor tissue demonstrates presence of a Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
The main exclusion criteria include but are not limited to the following:
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, chronic diarrhea)
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- Has known dihydropyrimidine dehydrogenase (DPD) deficiency
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization
- Has 1 or more conditions that, in the opinion of the investigator, make the participant ineligible for treatment with bevacizumab
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis or leptomeningeal disease
- Has active infection requiring systemic therapy
- Has not adequately recovered from major surgery or have ongoing surgical complications
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
머크연구 대표 연락처
연락처: Toll Free Number, 1-888-577-8839, [email protected]
137 23개국에 임상시험 장소
Kyonggi-do
National Cancer Center ( Site 0702), Goyang-si, Kyonggi-do, 10408, South Korea
Study Coordinator, 연락처, +82319201737
모집중
Seoul National University Bundang Hospital ( Site 0705), Seongnam-si, Kyonggi-do, 13620, South Korea
Study Coordinator, 연락처, +8215883369
모집중
The Catholic University of Korea St. Vincent s Hospital ( Site 0703), Suwon, Kyonggi-do, 16247, South Korea
Study Coordinator, 연락처, 82-31-881-8893
모집중
Seoul
Samsung Medical Center ( Site 0708), Gangnam, Seoul, 06351, South Korea
Study Coordinator, 연락처, +82234100297
모집중
Asan Medical Center ( Site 0707), Songpa-gu, Seoul, 05505, South Korea
Study Coordinator, 연락처, 82-2-3010-3204
모집중
Taegu-Kwangyokshi
Kyungpook National University Chilgok Hospital ( Site 0701), Buk-Gu, Taegu-Kwangyokshi, 41404, South Korea
Study Coordinator, 연락처, +82532003011
모집중
Seoul National University Hospital ( Site 0706), Seoul, 03080, South Korea
Study Coordinator, 연락처, +82-2-1588-5700
모집중
Korea University Guro Hospital ( Site 0704), Seoul, 08308, South Korea
Study Coordinator, 연락처, 82226263060
모집중
California
Los Angeles Hematology Oncology Medical Group ( Site 0084), Los Angeles, California, 90017, United States
Study Coordinator, 연락처, 213-533-9655
모집중
Florida
Orlando Health Cancer Institute ( Site 0065), Orlando, Florida, 32806, United States
Study Coordinator, 연락처, 321-841-6780
모집중
Iowa
University of Iowa ( Site 0074), Iowa City, Iowa, 52242, United States
Study Coordinator, 연락처, 319-356-4200
모집중
Kentucky
University of Kentucky ( Site 0055), Lexington, Kentucky, 40536, United States
Study Coordinator, 연락처, 859-218-1758
모집중
Norton Cancer Institute, Audubon Hospital Campus ( Site 0054), Louisville, Kentucky, 40217, United States
Study Coordinator, 연락처, 502-636-7845
모집중
Maryland
Greater Baltimore Medical Center ( Site 0068), Baltimore, Maryland, 21204, United States
Study Coordinator, 연락처, 443-849-3051
모집중
Nebraska
University Of Nebraska Medical Center ( Site 0078), Omaha, Nebraska, 68198, United States
Study Coordinator, 연락처, 402-559-4000
모집중
Nevada
Renown Regional Medical Center ( Site 0056), Reno, Nevada, 89502, United States
Study Coordinator, 연락처, 775-982-4000
모집중
New Jersey
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0060), Hackensack, New Jersey, 07601, United States
Study Coordinator, 연락처, 551-996-5855
모집중
Ohio
Miami Valley Hospital South ( Site 0075), Centerville, Ohio, 45459, United States
Study Coordinator, 연락처, 937-438-2400
모집중
Utah
Community Cancer Trials of Utah ( Site 0086), Ogden, Utah, 84405, United States
Study Coordinator, 연락처, 801-689-3909
모집중
Virginia
University of Virginia ( Site 0080), Charlottesville, Virginia, 22908, United States
Study Coordinator, 연락처, 434-243-8237
모집중
Buenos Aires
Hospital Italiano de Buenos Aires ( Site 0102), Ciudad Autonoma de Buenos Aires, Buenos Aires, C1199ABB, Argentina
Study Coordinator, 연락처, +5491155960279
모집중
Instituto Alexander Fleming ( Site 0101), Mar del Plata, Buenos Aires, C1426ANZ, Argentina
Study Coordinator, 연락처, +5491166936669
모집중
Santa Fe Province
Fundacion Estudios Clinicos ( Site 0105), Rosario, Santa Fe Province, S2000CEJ, Argentina
Study Coordinator, 연락처, +5493413168137
모집중
Hospital Privado Universitario de Córdoba ( Site 0108), Córdoba, X5016KEH, Argentina
Study Coordinator, 연락처, +543514688846
모집중
Queensland
Sunshine Coast University Hospital ( Site 0451), Birtinya, Queensland, 4575, Australia
Study Coordinator, 연락처, +61752020000
모집중
Victoria
Monash Health ( Site 0454), Clayton, Victoria, 3168, Australia
Study Coordinator, 연락처, +61 03 8572-2941
모집중
Western Health-Sunshine & Footscray Hospitals ( Site 0450), St Albans, Victoria, 3021, Australia
Study Coordinator, 연락처, +61383959167
모집중
Pernambuco
Hospital de Câncer de Recife ( Site 0158), Recife, Pernambuco, 50040-000, Brazil
Study Coordinator, 연락처, +558132178084
모집중
Rio Grande do Sul
Hospital de Caridade de Ijuí ( Site 0150), Ijuí, Rio Grande do Sul, 98700-000, Brazil
Study Coordinator, 연락처, +55 55 981580022
모집중
Associação Hospitalar Beneficente São Vicente de Paulo ( Site 0153), Passo Fundo, Rio Grande do Sul, 99010-080, Brazil
Study Coordinator, 연락처, +555433164000
모집중
Hospital Nossa Senhora da Conceição ( Site 0156), Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
Study Coordinator, 연락처, +5551993590437
모집중
Santa Catarina
CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina ( Site 0157), Florianópolis, Santa Catarina, 88020-210, Brazil
Study Coordinator, 연락처, +554833804828
모집중
São Paulo
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0155), Barretos, São Paulo, 14784-400, Brazil
Study Coordinator, 연락처, +551733216600
모집중
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0159), São José do Rio Preto, São Paulo, 15090-000, Brazil
Study Coordinator, 연락처, +55 17 3201-5054
모집중
COE Ensino e Pesquisa ( Site 0151), São José dos Campos, São Paulo, 12242-660, Brazil
Study Coordinator, 연락처, +5511960903468
모집중
Instituto do Cancer Arnaldo Vieira de Carvalho ( Site 0160), São Paulo, 01209-000, Brazil
Study Coordinator, 연락처, +55 11 3225-0155
모집중
IBCC - Núcleo de Pesquisa e Ensino ( Site 0154), São Paulo, 04014-002, Brazil
Study Coordinator, 연락처, +551134744222
모집중
New Brunswick
Moncton Hospital - Horizon Health Network ( Site 0011), Moncton, New Brunswick, E1C 6Z8, Canada
Study Coordinator, 연락처, 5068575756
모집중
Ontario
Princess Margaret Cancer Centre ( Site 0001), Toronto, Ontario, M5G 2M9, Canada
Study Coordinator, 연락처, 416-946-4559
모집중
Anhui
Anhui Provincial Cancer Hospital ( Site 0803), Hefei, Anhui, 230031, China
Study Coordinator, 연락처, 0551-65327666
모집중
The Second Affiliated Hospital of Anhui Medical University ( Site 0813), Hefei, Anhui, 230601, China
Study Coordinator, 연락처, 0551-63869536
모집중
Beijing Municipality
Peking Union Medical College Hospital ( Site 0824), Beijing, Beijing Municipality, 100730, China
Study Coordinator, 연락처, 8613910113193
모집중
Peking University First Hospital(Daxing Area) ( Site 0838), Beijing, Beijing Municipality, 102627, China
Study Coordinator, 연락처, 010-56957544
모집중
Chongqing Municipality
Chongqing University Cancer Hospital ( Site 0808), Chongqing, Chongqing Municipality, 400030, China
Study Coordinator, 연락처, 13983841209
모집중
Chongqing University Three Gorges Hospital ( Site 0837), Wanzhou, Chongqing Municipality, 404199, China
Study Coordinator, 연락처, 023-58103019
모집중
Fujian
Fujian Cancer Hospital ( Site 0807), Fuzhou, Fujian, 350014, China
Study Coordinator, 연락처, +86 13509339525
모집중
The First Affiliated Hospital of Xiamen University ( Site 0806), Xiamen, Fujian, 361003, China
Study Coordinator, 연락처, +86 13575559341
모집중
Guangdong
Sun Yat-Sen University Cancer Center ( Site 0800), Guangzhou, Guangdong, 510060, China
Study Coordinator, 연락처, +86 02087343565
모집중
Southern Medical University Nanfang Hospital ( Site 0812), Guangzhou, Guangdong, 510515, China
Study Coordinator, 연락처, +86 02062786845
모집중
The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 0828), Guangzhou, Guangdong, 510655, China
Study Coordinator, 연락처, 020-38254000
모집중
Guangxi
Guangxi Medical University Affiliated Tumor Hospital ( Site 0804), Nanning, Guangxi, 530200, China
Study Coordinator, 연락처, +86 07715323175
모집중
Henan
Henan Cancer Hospital ( Site 0822), Zhengzhou, Henan, 450008, China
Study Coordinator, 연락처, 037165587161
모집중
Hubei
Tongji Hospital Tongji Medical,Science & Technology ( Site 0839), Wuhan, Hubei, 430030, China
Study Coordinator, 연락처, 027-83663940
모집중
Hubei Cancer Hospital ( Site 0814), Wuhan, Hubei, 430079, China
Study Coordinator, 연락처, 027-87670500
모집중
Hunan
The Third Xiangya Hospital of Central South University ( Site 0834), Changsha, Hunan, 410013, China
Study Coordinator, 연락처, 0731-88638888
모집중
Jiangsu
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0825), Nanjing, Jiangsu, 210000, China
Study Coordinator, 연락처, 025-83106666
모집중
Jiangxi
The First Affiliated Hospital of Nanchang University ( Site 0826), Nanchang, Jiangxi, 330200, China
Study Coordinator, 연락처, 0791-88692748
모집중
Shandong
Jinan Central Hospital ( Site 0817), Jinan, Shandong, 250013, China
Study Coordinator, 연락처, 0531-55739999
모집중
Shanghai Municipality
Fudan University Shanghai Cancer Center ( Site 0816), Shanghai, Shanghai Municipality, 200120, China
Study Coordinator, 연락처, 021-64175590
모집중
Shanxi
First Affiliated Hospital of Shanxi Medical University ( Site 0843), Taiyuan, Shanxi, 030001, China
Study Coordinator, 연락처, 0351-4639931
모집중
Sichuan
Sichuan Cancer hospital. ( Site 0831), Chengdu, Sichuan, 610213, China
Study Coordinator, 연락처, 028-85420509
모집중
Yunnan
First Affiliated Hospital of Kunming Medical University ( Site 0845), Kunming, Yunnan, 650032, China
Study Coordinator, 연락처, 087165324888
모집중
Zhejiang
The Second Affiliated Hospital of Zhejiang University School of Medicine ( Site 0801), Hangzhou, Zhejiang, 310017, China
Study Coordinator, 연락처, 0571-87783777
모집중
Zhejiang Cancer Hospital ( Site 0821), Hangzhou, Zhejiang, 310022, China
Study Coordinator, 연락처, 0571-88122222
모집중
The First Affiliated Hospital of Wenzhou Medical University ( Site 0840), Wenzhou, Zhejiang, 325000, China
Study Coordinator, 연락처, +86057755579591
모집중
Cundinamarca
Hospital Universitario San Ignacio ( Site 0254), Bogota, Cundinamarca, 110231, Colombia
Study Coordinator, 연락처, +573152931879
모집중
Departamento de Córdoba
IMAT S.A.S ( Site 0252), Montería, Departamento de Córdoba, 230002, Colombia
Study Coordinator, 연락처, +576047862333
모집중
Risaralda Department
Oncologos Del Occidente ( Site 0255), Pereira, Risaralda Department, 660001, Colombia
Study Coordinator, 연락처, +57 3187715522
모집중
Pirkanmaa
Tampere University Hospital ( Site 1001), Tampere, Pirkanmaa, 33520, Finland
Study Coordinator, 연락처, +358503375000
모집중
Uusimaa
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1000), Helsinki, Uusimaa, 00290, Finland
Study Coordinator, 연락처, +358504272703
모집중
Alpes-Maritimes
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 1058), Nice, Alpes-Maritimes, 06202, France
Study Coordinator, 연락처, +33492036021
모집중
Calvados
Centre François Baclesse ( Site 1061), Caen, Calvados, 14000, France
Study Coordinator, 연락처, +33231455050
모집중
Lorraine
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois ( Site 1053), Vandœuvre-lès-Nancy, Lorraine, 54511, France
Study Coordinator, 연락처, +33772081634
모집중
Marne
Institut Jean Godinot ( Site 1054), Reims, Marne, 51100, France
Study Coordinator, 연락처, +33326504246
모집중
Pays de la Loire Region
Institut de Cancérologie de l'Ouest ( Site 1062), Angers, Pays de la Loire Region, 49055, France
Study Coordinator, 연락처, +33241352700
모집중
Seine-Maritime
CHU Charles Nicolle ( Site 1066), Rouen, Seine-Maritime, 76031, France
Study Coordinator, 연락처, +33232888148
모집중
Vaucluse
Sainte Catherine Institut du Cancer Avignon Provence ( Site 1065), Avignon, Vaucluse, 84918, France
Study Coordinator, 연락처, +33490276161
모집중
Katholisches Marienkrankenhaus gGmbH ( Site 1103), Hamburg, 22087, Germany
Study Coordinator, 연락처, 00494025460
모집중
Prince of Wales Hospital. ( Site 0500), Hong Kong, Hong Kong
Study Coordinator, 연락처, + 852 3505 2211
모집중
Queen Mary Hospital ( Site 0501), Hong Kong, Hong Kong
Study Coordinator, 연락처, +852 2255 3838
모집중
Rambam Health Care Campus ( Site 1253), Haifa, 3109601, Israel
Study Coordinator, 연락처, +97247776234
모집중
Hadassah Medical Center ( Site 1252), Jerusalem, 9112001, Israel
Study Coordinator, 연락처, 02-6777111
모집중
Rabin Medical Center ( Site 1251), Petah Tikva, 4941492, Israel
Study Coordinator, 연락처, 03-9377589
모집중
Sheba Medical Center ( Site 1254), Ramat Gan, 5265601, Israel
Study Coordinator, 연락처, +97235303030
모집중
Cagliari
AOU Cagliari ( Site 1306), Monserrato, Cagliari, 09042, Italy
Study Coordinator, 연락처, +39 07051096037
모집중
Ospedale San Raffaele. ( Site 1305), Milan, 20132, Italy
Study Coordinator, 연락처, +39.0226435138
모집중
Azienda Ospedaliera Universitaria dell'Università "Luigi Van-UOC Oncoematologia ( Site 1302), Naples, 80131, Italy
Study Coordinator, 연락처, 00390815666760
모집중
Istituto Oncologico Veneto IRCCS ( Site 1307), Padua, 35128, Italy
Study Coordinator, 연락처, 390498215910
모집중
Azienda USL della Romagna ( Site 1303), Ravenna, 48100, Italy
Study Coordinator, 연락처, 00390544285247
모집중
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma ( Site 1304), Verona, 37134, Italy
Study Coordinator, 연락처, 00393200117982
모집중
Chiba
National Cancer Center Hospital East ( Site 0851), Kashiwa, Chiba, 277-8577, Japan
Study Coordinator, 연락처, +81-4-7133-1111
모집중
Hokkaido
Teine Keijinkai Hospital ( Site 0864), Sapporo, Hokkaido, 006-8555, Japan
Study Coordinator, 연락처, +81-11-681-8111
모집중
Kagawa-ken
Kagawa University Hospital ( Site 0861), Kita-gun, Kagawa-ken, 761-0793, Japan
Study Coordinator, 연락처, +81-87-891-2345
모집중
Miyagi
Tohoku University Hospital ( Site 0853), Sendai, Miyagi, 980-8574, Japan
Study Coordinator, 연락처, +81-22-717-7000
모집중
Osaka
Kindai University Hospital ( Site 0854), Sakai, Osaka, 590-0197, Japan
Study Coordinator, 연락처, +81-72-366-0221
모집중
Saitama
Saitama Medical University International Medical Center ( Site 0860), Hidaka, Saitama, 350-1298, Japan
Study Coordinator, 연락처, +81-42-984-4111
모집중
Tokyo
Nippon Medical School Hospital ( Site 0859), Bunkyo, Tokyo, 113-8603, Japan
Study Coordinator, 연락처, +81-3-3822-2131
모집중
National Cancer Center Hospital ( Site 0850), Chūō, Tokyo, 104-0045, Japan
Study Coordinator, 연락처, +81-3-3542-2511
모집중
Cancer Institute Hospital of JFCR ( Site 0863), Koto, Tokyo, 135-8550, Japan
Study Coordinator, 연락처, +81-3-3520-0111
모집중
Kyushu University Hospital ( Site 0862), Fukuoka, 812-8582, Japan
Study Coordinator, 연락처, +81-92-642-5774
모집중
Gelderland
Radboudumc ( Site 1354), Nijmegen, Gelderland, 6525 GA, Netherlands
Study Coordinator, 연락처, +31 24 3610353
모집중
North Brabant
Amphia Ziekenhuis, locatie Breda Molengracht ( Site 1352), Breda, North Brabant, 4818 CK, Netherlands
Study Coordinator, 연락처, +31 76 5951006
모집중
North Holland
Amsterdam UMC, locatie VUmc ( Site 1351), Amsterdam, North Holland, 1081 HV, Netherlands
Study Coordinator, 연락처, +31204444321
모집중
Greater Poland Voivodeship
Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie ( Site 1457), Poznan, Greater Poland Voivodeship, 61-866, Poland
Study Coordinator, 연락처, +48943488930
모집중
Cluj
Institutul Oncologic Cluj ( Site 1502), Cluj-Napoca, Cluj, 400015, Romania
Study Coordinator, 연락처, +40 264 598 362
모집중
SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 1501), Cluj-Napoca, Cluj, 407280, Romania
Study Coordinator, 연락처, 021 9368
모집중
Dolj
Centrul de Oncologie Sfantul Nectarie-Medical ( Site 1500), Craiova, Dolj, 200746, Romania
Study Coordinator, 연락처, +40 731 604 432
모집중
Fundeni Clinical Institute-Medical Oncology ( Site 1504), Bucharest, 022328, Romania
Study Coordinator, 연락처, +4021 275 0500
모집중
Institutul Regional de Oncologie ( Site 1505), Iași, 700483, Romania
Study Coordinator, 연락처, +40374278811
모집중
Central Singapore
National Cancer Centre Singapore ( Site 0650), Singapore, Central Singapore, 168583, Singapore
Study Coordinator, 연락처, +6564368000
모집중
Barcelona
Institut Català d'Oncologia (ICO) - Badalona ( Site 1552), Badalona, Barcelona, 08916, Spain
Study Coordinator, 연락처, 34 934 97 89 25
모집중
Cantabria
Hospital Universitario Marqués de Valdecilla ( Site 1551), Santander, Cantabria, 39008, Spain
Study Coordinator, 연락처, +34 942202525
모집중
Las Palmas
Hospital Insular de Gran Canaria ( Site 1558), Las Palmas de Gran Canaria, Las Palmas, 35016, Spain
Study Coordinator, 연락처, 34 928441738
모집중
Principality of Asturias
Hospital Universitario Central de Asturias ( Site 1550), Oviedo, Principality of Asturias, 33011, Spain
Study Coordinator, 연락처, 34 985108000x36582
모집중
Hospital Universitari Vall d'Hebron ( Site 1553), Barcelona, 08035, Spain
Study Coordinator, 연락처, +34 93 489 43 50
모집중
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 1554), Madrid, 28007, Spain
Study Coordinator, 연락처, +34914269325
모집중
Hospital Clinico San Carlos ( Site 1555), Madrid, 28040, Spain
Study Coordinator, 연락처, 34913303000x484833
모집중
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1556), Seville, 41013, Spain
Study Coordinator, 연락처, +34 955 013 068
모집중
Instituto Valenciano de Oncologia - IVO ( Site 1557), Valencia, 46009, Spain
Study Coordinator, 연락처, 34961114000
모집중
National Cheng Kung University Hospital ( Site 0754), Tainan, 704, Taiwan
Study Coordinator, 연락처, +88662353535
모집중
National Taiwan University Hospital ( Site 0751), Taipei, 100, Taiwan
Study Coordinator, 연락처, +886-2-23123456
모집중
Taipei Veterans General Hospital ( Site 0752), Taipei, 112, Taiwan
Study Coordinator, 연락처, +886228712121
모집중
Chang Gung Memorial Hospital - Linkou Branch ( Site 0753), Taoyuan District, 333, Taiwan
Study Coordinator, 연락처, +88633281200
모집중
Cherkasy Oblast
MNE "Clinical Center of Oncology, Hematology, Transplantology and Palliative Care of CRC" ( Site 1706), Cherkasy, Cherkasy Oblast, 18009, Ukraine
Study Coordinator, 연락처, +380472319418
모집중
Chernivetska Oblast
RMNE "Bukovyna Clinical Oncology Center" ( Site 1709), Chernivtsi, Chernivetska Oblast, 58013, Ukraine
Study Coordinator, 연락처, 0443344770
모집중
Ivano-Frankivsk Oblast
MNPE "Prykarpattia Clinical Oncology Center of Ivano-Frankivsk Regional Council" ( Site 1701), Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine
Study Coordinator, 연락처, +380966059053
모집중
Kirovohrad Oblast
CNE "Regional Clinical Oncology Center of the Kirovohrad Regional Council" ( Site 1702), Kropyvnytskyi, Kirovohrad Oblast, 25011, Ukraine
Study Coordinator, 연락처, +380508427973
모집중
Lviv Oblast
MNPE LTMU Multidisc. Clin. Hosp. of Emerg. and Intens. Care ( Site 1708), Lviv, Lviv Oblast, 79059, Ukraine
Study Coordinator, 연락처, +380977453295
모집중
Rivne Oblast
MNE "Central City Hospital" ( Site 1711), Rivne, Rivne Oblast, 33017, Ukraine
Study Coordinator, 연락처, +380508266088
모집중
Volyn Oblast
ME "Volyn Regional Clinical Hospital" of the VRC ( Site 1712), Lutsk, Volyn Oblast, +380332773100, Ukraine
Study Coordinator, 연락처, 380503782998
모집중
Zakarpattia Oblast
Uzhgorod Central City Clinical Hospital ( Site 1700), Uzhhorod, Zakarpattia Oblast, 88000, Ukraine
Study Coordinator, 연락처, +380953274431
모집중
Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 1704), Kyiv, 03057, Ukraine
Study Coordinator, 연락처, +380669472333
모집중
SI "National Institute of Surgery and Transplantology named after O. O. Shalimov" ( Site 1713), Kyiv, 03126, Ukraine
Study Coordinator, 연락처, +380956017249
모집중
LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 1703), Kyiv, 03151, Ukraine
Study Coordinator, 연락처, +380671502987
모집중
London, City of
University College London Hospitals ( Site 1750), London, London, City of, NW1 2PG, United Kingdom
Study Coordinator, 연락처, 020 3456 7890
모집중
Oxfordshire
Churchill Hospital ( Site 1756), Oxford, Oxfordshire, ox3 7le, United Kingdom
Study Coordinator, 연락처, +4403003047777
모집중
The Christie NHS Foundation Trust ( Site 1755), Manchester, M20 4BX, United Kingdom
Study Coordinator, 연락처, +441614468370
모집중